Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: • Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • The effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; • Disruptions or inefficiencies in our supply chain, logistics, or operations; • Changes in laws and regulations in jurisdictions where we conduct business, including with respect to plastics and climate change; • Fluctuations in raw material prices, quality and supply, and in energy prices and supply; • Demand for our products and services; • Production outages or material costs associated with scheduled or unscheduled maintenance programs; • Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • Our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; • Information systems failures and cyberattacks; • Amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; • Our ability to achieve strategic objectives and successfully integrate acquisitions, including the implementation of a cloud-based enterprise resource planning system, S/4HANA; • Other factors affecting our business beyond our control, including without limitation, changes in the general economy, changes in interest rates, changes in the rate of inflation, geopolitical conflicts and any recessionary conditions; and • Other factors described in our Annual Report on Form 10-K for the year ended December 31, 2023 under Item 1A, “Risk Factors.” You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission. FX +4.6% FX -1.5% Total Avient +3.1% Note: Regional Sales Percentages exclude impact of foreign exchange Q2 2024 SEGMENT PERFORMANCE ( C O L O R , A D D I T I V E S & I N K S ) $525 $542 Q2 23 Q2 24 $94 $108 Q2 23 Q2 24 19.9% Sales Adjusted EBITDA (in millions) (in millions) Sales Adjusted EBITDA 10 17.9% +200 bps * * * Adjusted EBITDA Margin % • Organic sales growth in all regions led by Americas • Raw material deflation combined with cost reduction actions drove EBITDA margin expansion + 3% (+5% excluding FX) + 15% (+17% excluding FX) Q2 2024 SEGMENT PERFORMANCE ( S P E C I A LT Y E N G I N E E R E D M AT E R I A L S ) $301 $308 Q2 23 Q2 24 $60 $64 Q2 23 Q2 24 20.6% Sales Adjusted EBITDA (in millions) (in millions) Sales Adjusted EBITDA 11 19.8% +80 bps * * * Adjusted EBITDA Margin % • Sales growth in consumer, healthcare and building & construction end markets offset by weaker demand in telecommunications • EBITDA margin expansion driven by positive end market mix as well as raw material deflation + 2% (+4% excluding FX) + 7% (+8% excluding FX) 2 0 2 4 G U I D A N C E FY 20 24 GUIDA NC E Previous (May 7) Current Adjusted EBITDA $510 to $535 million $515 to $540 million Adjusted EPS $2.50 to $2.65 $2.55 to $2.70 Interest Expense $105 million $105 million Adjusted Effective Tax Rate 23% to 25% 23% to 25% Capital Expenditures ~$140 million ~$140 million 13 Q3 2024: Adjusted EPS of $0.62 14 Highlights • Provides performance updates on 2030 Sustainability Goals • Reduced company’s Scope 1 & 2 GHG emissions by 48% since 2019 • Highlights ESG performance ratings, certifications, and awards, including recent upgrades by Ecovadis to Gold and CDP to A- • Reflects Great Place to Work® culture focused on health, safety and employee engagement 20 23 SUSTAI NA BILI TY REPORT 14 Sustainability for a Better Tomorrow 2023 SUSTAINABILITY REPORT 15 • Investor Day to be held December 4, 2024 in New York, NY • The focus will be to do a deep dive on the Company’s strategy • Further details to be communicated 20 24 AVI ENT INVESTOR DAY A P P E N D I X 18 Performance Additives 15% Pigments 13% TiO2 9% Dyestuffs 2% Polyethylene 10%Nylon 5% Polypropylene 4% Styrenic Block Copolymer 4% Other Raw Materials 38% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials RA W MATERI AL BA SKET SEGMENT DATA U.S. & Canada 41% EMEA 36% Asia 18% Latin America 5% 2023 SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 19% Packaging 23%Industrial 16% Building and Construction 9% Telecommunications 4% Energy 5% Defense 7% END MARKET REVENUE $2,007M $358M $1,138M $224M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $502M$3,143M (1) Transportation 10% Healthcare 7% 20 (1) Total company sales and adjusted EBITDA of $3,143M and $502M, respectively, include intercompany sales eliminations and corporate costs 2 0 2 3 R E V E N U E | $ 2 . 0 B I L L I O N US & Canada 34% EMEA 37% Asia 21% Latin America 8% END MARKET REGION 21 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 9% Building & Construction 10% Telecommunications 1% Energy 2% COLOR , AD DI TI VES & INKS 2 0 2 3 R E V E N U E | $ 1 . 1 B I L L I O N US & Canada 52% EMEA 35% Asia 13% 22 Packaging 5% Consumer 16% Healthcare 6%Industrial 16% Transportation 12% Telecommunications 9% Energy 10% Defense 18% Building & Construction 8% END MARKET REGION SPEC IA LTY ENGI NEER ED MATERI ALS Packaging 32% Consumer 26% Healthcare 9% Industrial 13% Building & Construction 6% Telecommunications 2% Energy 2% Defense 1% Asia (18% of sales) Transportation 9% 2 0 2 3 AV I E N T R E G I O N A L S A L E S Packaging 25% Consumer 13% Healthcare 5% Industrial 18% Building & Construction 9% Energy 5% Defense 8% EMEA (36% of sales)Transportation 13% Packaging 13% Consumer 22% Healthcare 10% Industrial 16% Building & Construction 12% Energy 6% Defense 8% US & Canada (41% of sales) Transportation 9% Packaging 59% Consumer 22% Healthcare 2% Industrial 8% Building & Construction 4% LATAM (5% of sales) Transportation 5% Telecommunications 4% Telecommunications 4% 23 B Y E N D M A R K E T Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 43 Capex / Revenue 2022E (%) AV I E N T I S A S S E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 4 3 3 5 5 7 7 8 11 A vi en t A vi en t P F F U L K W R P P G R P M A V Y F M C H U N H X L E C L E M N C E A S H S C L Source: Peer data per Bloomberg market data as of April 21, 2022. Source: Peer data per Bloomberg market data as of April 21, 2022 86 82 86 86 84 78 77 89 86 81 80 76 76 76 67 67 11 (12) A vi en t A vi en t P F F U L K W R P P G R P M A V Y F M C U N V R B N R H U N H X L E C L C E A S H E M N S C L A LB 12% 18% 16% 15% 15% 14% 14% 28% 28% 26% 25% 22% 21% 19% 16% 12% 9% 9% A vi en t T od ay A vi en t P F A V Y P P G K W R FU L R P M C E A LB FM C A S H E C L E M N H X L H U N S C L B N R U N V R Median: 21%Median: 15% 2 0 2 2 E B I T DA M A RG I N S V S .

They recommended OnFlex-S™ K 65A-3E1709 multicomponent TPE, which offers excellent adhesion to ABS and can be molded at lower temperatures and injection pressures than competitive products. THE IMPACT With its enhanced processability, OnFlex-S K 65A-3E1709 thermoplastic elastomer enabled the company to solve its 2K molding issues and reduce system costs.

You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission. D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi e n t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x S U M M A RY: W H Y I N V E S T I N AV I E N T ?

You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.

You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the

You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the

With the assistance of management and any outside advisers the Committee deems appropriate (a) review and discuss with management the Company’s disclosures in the CD&A, and, based on this review, make a recommendation as to whether to include it in the Company’s annual report on Form 10-K and proxy statement relating to the Company’s 4 annual meeting of shareholders, and (b) prepare a Compensation Committee Report for inclusion in the Company’s proxy statement or other applicable SEC filings. Independence Assessment of Outside Advisers • The Committee may select a compensation consultant, legal counsel or other adviser to the Committee or receive advice from a compensation consultant, legal counsel or other adviser (other than in-house legal counsel or any compensation consultant, legal counsel or other adviser whose role is limited to the following activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K: consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of executive officers or directors of the Company, and that is available generally to all salaried employees; or providing information that either is not customized for a particular company or that is customized based on parameters that are not developed by the compensation consultant, and about which the compensation consultant does not provide advice) only after taking into consideration all factors relevant to that person’s independence from management, including the following: 5 • the provision of other services to the Company by the employer of the compensation consultant, legal counsel or other adviser; • the amount of fees received from the Company by the employer of the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the employer of the compensation consultant, legal counsel or other adviser; • the policies and procedures of the employer of the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest; • any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Committee; • any stock of the Company owned by the compensation consultant, legal counsel or other adviser; and • any business or personal relationship of the compensation consultant, legal counsel, other adviser or the employer of the adviser with an executive officer of the Company The Committee shall evaluate whether any compensation consultant retained or to be retained by it has any conflict of interest in accordance with Item 407(e)(3)(iv) of Regulation S-K.

With the assistance of management and any outside advisers the Committee deems appropriate (a) review and discuss with management the Company’s disclosures in the CD&A, and, based on this review, make a recommendation as to whether to include it in the Company’s annual report on Form 10-K and proxy statement relating to the Company’s annual meeting of shareholders, and (b) prepare a Compensation Committee Report for inclusion in the Company’s proxy statement or other applicable SEC filings. 4 Board Reports and Annual Evaluation The Committee is not required to assess the independence of any in-house legal counsel or compensation consultant, legal counsel, or other adviser whose role is limited to the 5 following activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K: consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of executive officers or non-employee directors of the Company, and that is available generally to all salaried employees; or providing information that either is not customized for a particular company or that is customized based on parameters that are not developed by the compensation consultant, and about which the compensation consultant does not provide advice The Committee shall evaluate whether any compensation consultant retained or to be retained by it has any conflict of interest in accordance with Item 407(e)(3)(iv) of Regulation S-K.